Management of Castration Resistant Prostate Cancer Current Clinical Urology Series
Auteur : Saad Fred
This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.
Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological Considerations
Chapter 1 - Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities
Chapter 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm
Chapter 3. Molecular Mechanisms of Prostate Cancer Progression after Castration
Chapter 4. New Imaging Modalities
Part II. TREATMENT - The Androgen Receptor Signaling Axis biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and Radiopharmaceuticals
Chapter 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer
Chapter 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer
Chapter 7. Approaches Targeting Androgen Synthesis (CYP 17 inhibitors)
Chapter 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations)
Chapter 9. The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer
Chapter 10. Bone Targeted Therapy: Rationale and Current Status
Chapter 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer
Part III. New Drug Development: Clinical Trials Design in CRPC
Chapter 12. Introduction
Chapter 13. Phase I/II targeted treatments
Chapter 14. Defining Clinical Endpoints in Castration-resistant Prostate Cancer
Part IV. New Drug Development: Specific Targets
Chapter 15. Angiogenesis Inhibition in Castration Resistant Prostate Cancer
Chapter 16. Co-targeting Adaptive Survival Pathways
Chapter 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer
Chapter 18. PARP Inhibitors
Chapter 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer
Chapter 20. Epigenetics in Castration Resistant Prostate Cancer
Chapter 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype
Part V. Clinical Management Aspects
Chapter 22. Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management
Chapter 23. Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development
All chapters are written by experts in their fields
Provides up to date guidelines and algorithms for management
Provides a concise yet comprehensive summary of the current status of the field
Date de parution : 02-2015
Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).
Prix indicatif 137,14 €
Ajouter au panier